Sign in
4

Changes in Ownership

Oruka Therapeutics, Inc. Filed Acc 0000907654-26-000075

Senior Vice President, Finance sold 10,000 shares at an average $106.66 ($1,066,572)

  • Senior Vice President, Finance acquired 10,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Agarwal Arjun · Senior Vice President, Finance

Table I: Non-derivative

7 lines
Date Transaction Shares Price Value Owned after D/I
2026-08-13 Exercise or conversion : show line 1 in the form 10b5-1 +8,542 $12.50 $106,775 23,854 D
2026-08-13 Exercise or conversion : show line 2 in the form 10b5-1 +1,458 $34.39 $50,141 25,312 D
2026-08-13 Sale : show line 3 in the form 10b5-1 −2,100 $104.67 $219,814 23,212 D
2026-08-13 Sale : show line 4 in the form 10b5-1 −2,132 $105.57 $225,079 21,080 D
2026-08-13 Sale : show line 5 in the form 10b5-1 −1,268 $106.63 $135,201 19,812 D
2026-08-13 Sale : show line 6 in the form 10b5-1 −2,142 $107.71 $230,723 17,670 D
2026-08-13 Sale : show line 7 in the form 10b5-1 −2,358 $108.46 $255,755 15,312 D
Open-market sales · 10,000 sh · avg $106.66 · $1,066,572

Table II: Derivative

2 lines
Date Transaction Shares Owned after D/I
2026-08-13 Exercise or conversion : show line 8 in the form 10b5-1 Employee Stock Option (right to buy) −8,542 92,917 D
2026-08-13 Exercise or conversion : show line 9 in the form 10b5-1 Employee Stock Option (right to buy) −1,458 59,792 D
Loading xslF345X06/form4.xml…